在心理健康患者中进行药物遗传测试的CYPRI评分的探索性,回顾性研究
Samira Marie Comtesse1, Ivana Tašková2,3, Nicole Safářová2,4,5
1Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Goethe University Frankfurt, 60528 Frankfurt, Germany.
Genes
|December 30, 2025
概括
修订后的CYP药物遗传风险评分 (CYPRI_cor) 改善了在精神病治疗中进行药物遗传 (PGx) 测试的患者选择. 这种工具增强了临床特异性,帮助临床医生识别PGx测试将最受益的患者.
科学领域:
- 药物遗传学 药物遗传学
- 精神病学药物治疗 精神病学药物治疗
- 临床决策支持 临床决策支持
背景情况:
- 药物遗传学 (PGx) 测试对于优化精神病学药物治疗至关重要,但由于成本和患者选择,它在日常使用中面临局限性.
- 该CYP药物遗传风险评分 (CYPRI) 是为了确定可能从PGx测试中受益的精神病患者而开发的.
- 这项研究评估和改进了CYPRI,以提高其临床适用性.
研究的目的:
- 评估原始CYPRI评分的临床相关性.
- 确定CYPRI的弱点并建议对其进行修改.
- 评估修订后的CYPRI评分 (CYPRI_cor) 在常规临床环境中的适用性.
主要方法:
- 来自法兰克福大学医院的92名抑郁症患者数据的回顾性分析.
- 评估原始CYPRI评分与PGx测试 (IMPACT评分) 的临床影响的关联.
- 使用顺序回归和ROC分析,随后开发并将修订后的CYPRI_cor应用于法兰克福和布拉格队列.
主要成果:
- 最初的CYPRI评分显示了检测非正常CYP2D6/CYP2C19代谢者的临床价值.
- 修订后的CYPRI_cor显示了改善的临床特异性,同时保持了差异性表现 (法兰克福AUC:0.68,布拉格:0.71).
- 在法兰克福,CYPRI_cor获得了0.69的特异性,确定切线≥4表明临床影响.
结论:
- 修改了CYPRI_cor以解决原始得分的局限性,特别是在归因ADR和权重TDM结果方面.
- 虽然在法兰克福数据集中,歧视性表现没有显著改善,但这些修改是有意义的.
- 需要进行前性研究来确认CYPRI_cor.的临床实用性.
更多相关视频
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
598
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
598
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176
01:28Human Genetics
1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
01:12Analysis of Population Pharmacokinetic Data
643
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
643
01:29Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163